INTRODUCTION
Patients with chronic lymphocytic leukemia (CLL), which accounts for approximately one-third of adult leukemia in the United States, 1 may be vulnerable to psychological stress because chemoimmunotherapy is not curative. At diagnosis, patients may be asymptomatic except for high lymphocyte counts (>5000/mm 3 ). Closer inspection identifies small, mature-appearing lymphocytes with progressive B-lymphocyte accumulation in the blood stream, making CLL a disease in which a key biologic system-immunity-is compromised. 2 Treatments may bring remission, but relapses are likely to occur, and successive treatments often have greater toxicity and reduced effectiveness. 3 Thus, the relapsing/refractory nature of CLL places patients at risk of stress and, perhaps, stress-induced immune impairments.
Previous work has provided empirical support for how stress impacts immunity to initiate or facilitate an ongoing pathologic process. 4 The immune system is viewed as acting like a sensory organ, informing the brain of immune challenges; furthermore, immune activation may be interpreted by the central nervous system as a stressor. 5 Cytokines may be a part of the regulatory loop. 6 Indeed, "sickness behaviors," such as heightened negative emotions, are considered the products of proinflammatory cytokines. 5, 7 Conversely, data from psychological intervention trials indicate that, when patients' stress lowers, inflammation is reduced, and health and cancer outcomes are improved. 8, 9 Examining how stress interacts with the immune system in CLL is critical, because CLL cells develop in the same environment as normal immune cells. 10 Specifically, malignant cells interact with stromal cells as well as T cells in the lymphoid tissue, collectively creating a microenvironment conducive to the survival and proliferation of malignant cells. 11 CLL cells can be stimulated directly by elements of the microenvironment or through cytokines and chemokines. 12 In addition, lymphatic tissues are the principle site of B-cell receptor (BCR) activation for both normal and malignant B cells. 13 In response to BCR activation, CLL cells secrete chemokines, a type of cytokine that directs white blood cells to infected tissues to help create a microenvironment conducive to disease progression. 11 Additional research has indicated that BCR signaling results in malignant B-cell proliferation and may impede the immune system's ability to destroy malignant cells. 13 Considering these reports, we studied how stress might covary with the absolute lymphocyte count (ALC), the hallmark CLL indicator, 14 and with cytokine and chemokine factors important to the interaction of CLL cells and the microenvironment.
Tumor necrosis factor a (TNFa) is a cytokine involved in systemic inflammation and is produced by activated macrophages, although other cell types (such as cluster of differentiation 4 [CD4]-positive lymphocytes and natural killer [NK] cells) also produce TNFa. TNFa is increased in patients who have CLL compared with healthy individuals 15 and is correlated with higher white cell counts at diagnosis and shorter progression-free survival. 16, 17 In vitro data reveal that CLL neoplastic lymphocytes release TNFa spontaneously 15 and that exposure to TNFa increases the proliferation and viability of leukemic lymphocytes.
18
A proliferation-inducing ligand (APRIL) and the Bcell-activating factor of the TNF family (BAFF) are cytokines that aid in the survival and proliferation of CLL cells. 11, 19 In vitro data demonstrate that APRIL and BAFF aid CLL cell survival through the up-regulation of CD40 ligands. 20 Clinical data indicate that patients who had lower APRIL/BAFF expression in CLL cells had longer survival compared with those who had greater expression of APRIL/BAFF in CLL cells. 21 Furthermore, inflammatory cytokines, such as interleukins 6 (IL-6) and IL-10, are involved in promoting angiogenesis in CLL. 22 Researchers have demonstrated that B cells and CLL cells produce IL-10 and have suggested that IL-10 creates an immunosuppressive niche that allows CLL cells to proliferate. 23, 24 Elevated levels of IL-6 and IL-10 have been observed in patients who have CLL compared with controls and are associated with shorter survival. 16 A meta-analysis indicated that IL-10 expression predicted worse disease-free survival among patients who had hematologic malignancies. 25 Also relevant is IL-16, a proinflammatory cytokine that contributes to the pathogenesis of CLL through the regulation of CD4-positive cell recruitment and activation at sites of inflammation. 26 CLL cells produce high levels of angiogenic factors that support cell accumulation and proliferation. 27 Among the most studied angiogenic factors, vascular endothelial growth factor (VEGF) is secreted by malignant B cells. 28 Research has demonstrated that patients who have CLL with higher levels of VEGF have 3 times the increased risk of progressive disease. 29 In addition, malignant B cells secrete chemokine (C-C motif) ligand 3 (CCL3), which fosters the interaction between CLL cells and the leukemia microenvironment 30 and has been associated with advanced-stage disease. 31 Patients with relapsed/refractory CLL in a phase 2 (open-label) trial of a new targeted agent (ibrutinib) were studied. Past research has indicated that patients who have relapsed/refractory CLL have lower quality of life compared with treatment-naive patients 32, 33 and may be vulnerable to stress. Previous research also has demonstrated that a measure of cancer-specific stress 34 can predict lower NK cell cytotoxicity, diminished response of NK cells to recombinant interferon c, and decreased T-cell blastogenesis in patients with breast cancer who are awaiting chemotherapy. 35 Therefore, in a sample of patients with CLL, heightened stress may be associated with heightened CLL-specific cellular (ALC), cytokine (TNFa, APRIL, BAFF, IL-6, IL-10, IL-16, and VEGF), and chemokine (CCL3) markers while controlling for disease-relevant and behavioral correlates of inflammation.
MATERIALS AND METHODS

Design
A single-group observational design was used. Patients with relapsed/refractory CLL were screened and accrued to a phase 2 study of ibrutinib at the Ohio State University Medical Center. The trial is registered at clinicaltrials.gov as NCT01589302.
Participants and Procedures
The Institutional Review Board granted ethical approval for the study with an accrual goal of 154 patients. Informed written consent was obtained from 152 patients who had relapsed/refractory CLL during accrual (from May 2012 to July 2014). Descriptive data are displayed in Table 1 . In the clinic on day 1 of initial treatment, patients independently completed a self-report measure of stress (the Impact of Event Scale [IES]), provided descriptive information, and had their blood drawn.
Funding was sought to conduct immune assays. Of the 152 patients who consented to participate, 144 had adequate samples. Patients according to sex were rank ordered from highest to lowest on the IES score, and every other patient was selected for the first batch of cytokine/ chemokine assays (n 5 72). Later, funding was provided for a second batch of assays, in which 24 patients with the highest stress scores were selected. In total, 96 patient samples were available for the cytokine/chemokine assays.
Cancer
Measures
Stress
The IES-Revised 34, 36 assesses stress reactions in the form of intrusive thoughts (8 items), avoidant thoughts or behaviors (8 items), and hyperarousal (6 items), with items tailored to read "cancer stress" or "cancer." Previous research has demonstrated that the IES covaries with immunity in patients with breast cancer. 35 Patients rate the frequency of feelings or events in the past week on a scale ranging from 0 (not at all) to 4 (extremely), and all items are summed. Possible scores range from 0 to 88, with higher scores indicative of greater stress. In the current study, the coefficient a reliability was .89.
Immune
Absolute lymphocyte count. Nursing staff collected 6-mL potassium ethylene diamine tetra-acidic acid (lavender-top vacutainer) peripheral blood. Complete blood cell counts with ALCs were quantified by the hospital laboratories.
Cytokines and chemokines. Plasma samples were centrifuged, aliquoted into 4 samples, and frozen at 280 8C. Later, samples were thawed, batched by participant, and spun to remove debris. Assessment of plasma levels of cytokines (TNFa, APRIL, BAFF, IL-6, IL-10, IL-16, and VEGF) and the chemokine CCL3 were quantified using individual enzyme-linked immunosorbent assays in triplicate according to the manufacturer's specifications for each of the cytokines and chemokines (R&D Systems, Minneapolis, MN). Detection limits were 1.6 pg/mL for TNFa, 7.1 pg/mL for APRIL, 2.7 ng/mL for BAFF, 0.7 pg/mL for IL-6, 3.9 pg/mL for IL-10, 6.2 pg/mL for IL-16, 9.0 pg/mL for VEGF, and 10.0 pg/mL for CCL3. The interassay and intraassay coefficients of variation for all cytokines tested were 6.26% and 14.29%, respectively.
Covariates
Older age, male sex, the presence of multiple comorbidities, the number of prior treatments, and the presence of del17p (deletion of the short arm of chromosome 17) were included as covariates, because these factors are predictive of poorer outcomes in patients CLL. [37] [38] [39] [40] [41] Four areas were considered: 1) demographics (age and sex); 2) comorbidities according to the Charlson Comorbidity Index (CCI), 42 which is a measure of the risk of death from current diseases or conditions and has 19 items (eg, liver disease, diabetes mellitus), each weighted from 1 to 6 based on severity and mortality risk, which are summed for a total score (all patients received 2 points for having cancer, and a score >2 indicated the presence of comorbid conditions); 3) CLL severity and risk, as determined from the number of prior therapies received and genetic risk (presence of del17p); and 4) behavioral correlates of inflammation 43 (body mass index [BMI] and smoking status).
Analytic Plan
Preliminary analyses contrast patients in the cytokine/chemokine assay subgroup (n 5 96) and those not (n 5 56) on descriptive characteristics, covariates, and stress (IES), using independent-sample t tests for continuous variables and chi-square tests for categorical variables. For cytokine and chemokine values below detectable limits, the MICE package 44 for the R statistical software package (R Foundation for Statistical Computing, Vienna, Austria) was used to generate random values between zero and the minimum detectable level to increase variance. Multiple imputation has been used previously to impute cytokine and chemokine values. 45 Spearman correlations between each covariate and outcome variable were examined, and only covariates associated (P < .10) with an outcome were included in the analyses.
Multiple linear regressions (MLRs) were used in the analyses to test the concurrent relation between stress and ALC, cytokines, and chemokine responses after the entry of relevant covariates. For each outcome, step 1 included only the associated covariates as predictors, whereas step 2 included the associated covariates with the addition of IES scores as predictors of cellular, cytokine, and chemokine responses. The increment in the squared multiple correlation (R 2 ) from step 1 to step 2 provided the variance attributable to stress beyond the covariates. In addition, standardized regression betas (b) in step 2 indicated the magnitude and direction of the influence of stress on outcomes. General assumptions of linear regression, including multicollinearity, variance of errors, and normality of error distributions, were examined; if they were positively skewed, then variables were log transformed.
RESULTS
Preliminary
Patients with (n 5 96) and without (n 5 56) cytokine/ chemokine data did not differ (P .18) on any demographic, general health, CLL risk, or "behavioral correlates of inflammation" variables. Patients who had cytokine/ chemokine data available reported greater IES scores, (t[150] 5 3.04; P < .01). Minimum detectable levels were imputed using the MICE package for TNFa (5 patients), APRIL (6 patients), and IL-10 (2 patients).
Intercorrelations between covariates and ALC, cytokine, and chemokine markers were inspected. No outcome covaried with current smoking status. For the remaining variables, the following P < . 10 
Primary
Results of MLRs are displayed in Table 2 and indicated that stress was a significant predictor of higher ALC (b 5 .208, P 5 .037) (Fig. 1A) . In addition, the R 2 change between steps 1 and 2 indicated that stress accounted for 4.3% of the variance in ALC when controlling for age. Models examining cytokines and chemokines reveled that stress was a significant predictor of TNFa (b 5 .251; P 5 .016) (Fig. 1B) , IL-16 (b 5 .413; P < .001) (Fig.  1C) , and CCL3 (b 5 .230; P 5 .027) (Fig. 1D) such that higher levels of stress were associated with increased levels of these 3 outcomes (Fig. 1, B-D) . The R 2 change indicated that stress accounted for 6.3%, 17.0%, and 5.2% of the variance in TNFa, IL-16, and CCL3, respectively. Analyses with stress and IL-6, IL-10, and VEGF were not significant (P > .17 for all).
DISCUSSION
Novel data from patients with relapsed/refractory CLL indicate that increased stress is associated with multiple poor prognosis CLL biomarkers. Heightened stress covaried with higher ALC, a salient marker of CLL burden, along with TNFa and IL-16. In the biobehavioral literature, there are few studies of stress and chemokines 46, 47 and none of CCL3, which also covaried with stress. Effects were observed with outcome-specific controls for Cancer age, sex, BMI, comorbid illnesses, prior treatments, and/ or CLL genetic risk.
Meta-analyses of studies with adults who experience general stressors have demonstrated that heightened stress covaries with increases in lymphocyte numbers, 48, 49 whereas meta-analyses of stress from acute stressors reveal a lowering of lymphocyte numbers. 50 Both human lymphocyte data and leukemic animal paradigms 51 illustrate the adverse effects of chronic stress, an effect that may be especially pernicious in CLL.
The association between stress and TNFa is particularly important in CLL, because malignant cells release TNFa spontaneously, 15 and TNFa increases their proliferation and viability. 52 The current TNFa finding adds to the biobehavioral cancer literature, because most studies have reported that depression, rather than stress, is related to higher levels of TNFa. [53] [54] [55] Stress and depression can co-occur in patients, and future research may examine the independent and synergistic effects of depression and stress on inflammatory markers like TNFa. 56 Higher levels of stress also were associated with higher levels of IL-16. It has been suggested that IL-16 may mediate communications between B cells and T cells within lymph node follicles 57, 58 ; furthermore, IL-16 may suppresses effector T-cell function. [59] [60] [61] To our knowledge, the only other stress/IL-16 data come from a study of a naturalistic stressor (students' academic examinations) in which IL-16 was significantly elevated pre-examination versus postexamination. 62 It is noteworthy that no covariates were needed for the IL-16 analyses, and stress accounted for substantial variance (17%) in IL-16 prediction. Future research might explore the pathway of heightened stress, increased IL-16, and suppression of effector Tcell function, which may be relevant to autoimmune diseases 63 or other cancers 64 in which Il-16 plays an important role.
Although the function of CCL3 is not yet fully clarified, 31 it has been hypothesized that increased CCL3 secretion may induce the trafficking and homing of T cells to CLL cells in tissue microenvironments. 65 Moreover, by attracting immune cells for interaction with CLL cells and their microenvironment, CCL3 creates a circumstance in which CLL cells interact with T cells, providing survival and proliferation signals. 66 Some cytokines did not covary with stress: VEGF, BAFF, APRIL, IL-6, and IL-10. It is perhaps noteworthy that the number of prior therapies was a significant negative predictor for all outcomes except for IL-10, which , squared multiple correlation; TNFa, tumor necrosis factor a; VEGF, vascular endothelial growth factor. a Step 1 enters covariates associated (P <.10) with outcomes; and step 2 enters cancer-specific stress to predict log-transformed cellular, cytokine, and chemokine markers. b P <.05. Dashes indicate covariates that were not correlated (P >.01) with each outcome variable. c P <.01. Dashes indicate covariates that were not correlated (P >.01) with each outcome variable.
BLS
Cancer was not associated with any covariates. This highlights the general importance of including treatment variables in tests of stress. It also suggests possible limiting factor(s)-the disease, repeated treatments, or some combinationin detecting stress effects on immunity for patients with relapse/refractory CLL, as manifest in these specific assays. When stress was a significant predictor, the number of prior therapies was not correlated (entered) for ALC, IL-16, or CCL3 analyses and was entered but was not significant for TNFa analysis. Data like these are important for discerning the specific conditions under which the effects of stress may be detected. Although the use of these covariates may account for null findings, the results may be specific to CLL, because previous research suggests that stress is associated with increased levels of inflammatory cytokines in solid tumor cancers. For example, IL-6 may contribute to tumor suppression rather than immune suppression in CLL. 67 We also considered the strengths and limitations of the current study. Data were derived complete accrual to a phase 2 trial of an experimental therapy, an important study context for biobehavioral studies. When both effectiveness and toxicities are unclear, insights into psychological or behavioral factors and their interaction with disease-specific biomarkers add to the overall contribution of a phase 2 trial. Internal validity was strong; however, in a single-site trial at a comprehensive cancer center, patients generally have more resources, are younger, and are less diverse. 68, 69 Patients who have low-incidence blood cancers tend to receive treatment at regional centers, making the sample geographically diverse (patients traveled > 300 miles on average to receive treatment). Limited funds prevented an analysis of all trial patients (N 5 152), but a sample of 96 was comparatively large for an exploratory study. 70 The latter sample differed from the remainder only in terms of having a higher mean level of stress (IES), which was anticipated because of oversampling patients who had higher stress for the second batch of assays. Of the covariate candidates, age, sex, and the number of prior therapies were important; whereas del17p, comorbidity, and BMI played little if any role in the analyses, providing knowledge relevant to future studies. The cytokine/chemokine outcomes were chosen for their relevance to CLL; however, there are other outcomes important for study, 11 such as those for the T-cell compartment (CD8-positive, CD57), NK cells, and response to Bruton tyrosine kinase inhibition. Finally, because this was an exploratory study, the findings were not adjusted for multiple outcomes in parallel analyses.
Regarding the clinical contribution, other studies that used the IES to assess cancer stress reported that higher stress covaried with higher levels of CLL signs/symptoms (eg, fatigue, enlarged lymph nodes, infections, and others). 71 Stress also is an important individual difference variable that is predictive of future quality of life 71, 72 and is a moderator of intervention effectiveness. Patients with moderate-to-severe stress, anxiety, and/or depressive symptoms are in need of early, evidence-based, psychological treatment to address current difficulties and lower the likelihood of poorer quality of life, which otherwise may follow. 73 Selected intervention trials have resulted in increased T-cell immunity, 74 greater production of type 1 T-helper (Th1) cytokines (IL-2, IL-12, and interferon c), 75, 76 and decreases in Th2 cytokines (IL-4 and IL-10). 76 In conclusion, novel biobehavioral data from patients with relapsed/refractory CLL reveal that psychological stress is related to heightened levels of cellular, cytokine, and chemokine markers that are associated with progressive disease. Understanding the association between psychological stress and host factors, particularly immunity, is needed. Although previous research has examined stress associations in animal models, 51 to our knowledge, this is the first biobehavioral study to demonstrate that stress covaries with 4 key biomarkers in patients with CLL. The current data are consistent with the hypothesis that stress may be a negative interface to an already weakened immune system. Replication and longitudinal data will be needed to clarify the trajectories of these responses and any relevance to CLL relapse.
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